

ERRATUM

Erratum to: Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials

Uzoma N. Ibebuogu¹ · Oluwaseyi Bolorunduro¹ · Smith Giri¹ · Sam Dagogo-Jack² · Blake G. Smith¹ · Saibal Kar³ · Guy L. Reed¹

Published online: 1 April 2015
© Springer International Publishing Switzerland 2015

Erratum to: Am J Cardiovasc Drugs DOI 10.1007/s40256-015-0113-8

Key points, second sentence which previously read:

The benefits of bivalirudin were seen mainly in DM patients undergoing effective PCI.

Should read:

The benefits of bivalirudin were seen mainly in DM patients undergoing elective PCI.

The online version of the original article can be found under doi:[10.1007/s40256-015-0113-8](https://doi.org/10.1007/s40256-015-0113-8).

✉ Uzoma N. Ibebuogu
uibebug@uthsc.edu; Ibebuogu@gmail.com

¹ Division of Cardiovascular Diseases, University of Tennessee Health Sciences Center, 365 Court Avenue, Suite D334, Memphis, TN 38163, USA

² Division of Endocrinology, University of Tennessee Health Sciences Center, Memphis, TN, USA

³ Heart Institute, Cedars-Sinai Heart Institute, Los Angeles, CA, USA